Potential pharmacological uses of chalcones: A patent review (from June 2011-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 3, 2015, Pages 351-366

  Matos, Maria João ^a   Vazquez Rodriguez, Saleta ^a   Uriarte, Eugenio ^a   Santana, Lourdes ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chalcones; Natural extracts; Pharmacological properties; Synthesis

Indexed keywords

CHALCONE DERIVATIVE; DIHYDROCHALCONE DERIVATIVE; ISOBAVACHALCONE DERIVATIVE; ISOLIQUIRITIGENIN; LICOCHALCONE DERIVATIVE; NARDOARISTOLONE; UNCLASSIFIED DRUG; XANTHOANGELOL; XANTHOHUMOL;

CHINESE MEDICINE; CLAISEN CONDENSATION; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; DRUG USE; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; SYNTHESIS;

CHALCONES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922827822     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.995627     Document Type: Review

References (111)

1. Di Carlo G, Mascolo N, Izzo AA, et al. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53
2. Sahu NK, Balbhadra SS, Choudhary J, et al. Exploring pharmacological significance of chalcone scaffold: a review. Curr Med Chem 2012;19(2):209-25
3. Nowakowska Z. A review of antiinfective and anti-inflammatory chalcones. Eur J Med Chem 2007;42:125-37
4. Lawrence NJ, Patterson RP, Ooi LL, et al. Effects of alpha-substitutions on structure and biological activity of anticancer chalcones. Bioorg Med Chem Lett 2006;16:5844-8
5. Bukhari SNA, Jasamai M, Jantan I, et al. Reviews of methods and various catalysts used for chalcone synthesis. Mini-Rev Org Chem 2013;10:73-83
6. Guida A, Lhouty MH, Tichit D, et al. Hydrotalcites as base catalysts. Kinetics of Claisen-Schmidt condensation, intramolecular condensation of acetonylacetone and synthesis of chalcone. Appl Catal A 1997;164:251-64
7. Mukaiyama T. The directed aldol reaction. Org React 1982;28:203-331
8. Eddarir S, Cotelle N, Bakkour Y, et al. An efficient synthesis of chalcones based on the Suzuki reaction. Tetrahedron Lett 2003;44:5359-63
9. Al-Masum M, Ng E, Wai M. Palladium-catalyzed direct cross-coupling of potassium styryltrifluoroborates and benzoyl chlorides-A one step method for chalcone synthesis. Tetrahedron Lett 2011;52:1008-10
10. Zou G, Guo J, Wang Z, et al. Heck-Type coupling vs. conjugate addition in phosphine-rhodium catalyzed reactions of aryl boronic acids with alpha, beta-unsaturated carbonyl compounds: a systematic investigation. Dalton Trans 2007;28:3055-64
11. Bohm A. Introduction to flavonoids. Harwood Academic Pub; London: 1998
12. Kumar A, Sharma S, Tripathi VD, et al. Synthesis of chalcones and flavanones using Julia-Kocienski olefination. Tetrahedron 2010;66:9445-9
13. Singh P, Anand A, Kumar V. Recent developments in biological activities of chalcones: a mini review. Eur J Med Chem 2014;85C:758-77
14. Singh P, Raj R, Kumar V, et al. 1, 2, 3-Triazole tethered beta-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation. Eur J Med Chem 2012;47:594-600
15. Mai CW, Yaeghoobi M, Rahman NA, et al. Chalcones with electronwithdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-Activity relationship analysis and regulation of apoptotic proteins. Eur J Med Chem 2014;77:378-87
16. Winter E, Pizzol CD, Locatelli C, et al. In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies. Int J Environ Res Public Health 2014;11(10):10016-35
17. P-erez-Cruz F, Vazquez-Rodriguez S, Matos MJ, et al. Synthesis and electrochemical and biological studies of novel coumarin-chalcone hybrid compounds. J Med Chem 2013;56(15):6136-45
18. Aly M, Fodah H, Saleh SY. Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes. Eur J Med Chem 2014;76:517-30
19. Vazquez-Rodriguez S, Matos MJ, Santana L, et al. Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists. J Pharm Pharmacol 2013;65(5):697-703
20. Sinha S, Medhi B, Sehgal R. Chalcones as an emerging lead molecule for antimalarial therapy: a review. J Modern Med Chem 2013;1:64-77
21. Guantai EM, Ncokazi K, Egan TJ, et al. Enone-And chalcone-chloroquinoline hybrid analogues: in silico guided design, synthesis, antiplasmodial activity, in vitro metabolism, and mechanistic studies. J Med Chem 2011;54:3637-49
22. Yin BT, Yan CY, Peng XM, et al. Synthesis and biological evaluation of alpha-Triazolyl chalcones as a new type of potential antimicrobial agents and their interaction with calf thymus DNA and human serum albumin. Eur J Med Chem 2014;71:148-59
23. Sharma H, Patil S, Sanchez TW, et al. Synthesis, biological evaluation and 3DQSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorg Med Chem 2011;19:2030-45
24. Fatima S, Sharma A, Saxena R, et al. One pot efficient diversity oriented synthesis of polyfunctional styryl thiazolopyrimidines and their bioevaluation as antimalarial and anti-HIV agents. Eur J Med Chem 2012;55:195-204
25. Anthwal A, Rajesh UC, Rawat MS, et al. Novel metronidazole-chalcone conjugates with potential to counter drug resistance in Trichomonas vaginalis. J Med Chem 2014;79:89-94
26. Bello ML, Chiaradia LD, Dias LR, et al. Trimethoxy-chalcone derivatives inhibit growth of Leishmania braziliensis: synthesis, biological evaluation, molecular modeling and structure-Activity relationship (SAR). Bioorg Med Chem Lett 2011;19:5046-52
27. Zhengzhou University. Method for extracting active ingredients from Chinese medicine Dalbergia and their application as cardiovascular agent. CN102119957; 2011
28. Paek KS. Dalbergia odorifera extracts and compounds separated therefrom for preventing skin aging. WO2011108821
29. Hanbul Cosmetics Co Ltd. External skin care agent containing glycyrrhizae radix extract with increased isoliquiritigenin content. KR20120081289
30. Hanbul Cosmetics Co Ltd. Isoliquiritigenin for improving hypnotic effect. KR20120078898
31. Shandong Eye Inst. Eye drops of isoliquiritigenin and its preparation method. CN102488674; 2012
32. Capital Medical University. Application of isoliquiritigenin in medicine for preventing and/or treating cardiocerebrovascular disease. CN102247339; 2011
33. Adbiotech Co Ltd. Method for extracting functional components from Glycyrrhiza inflate. KR0107652; 2012
34. Dermatologiques D Uriage Lab. Cosmetic composition for the treatment of oily skin. FR2997626; 2014
35. Beiersdorf Ag. Hair styling formulation for generating flexible hold by application of licochalcone A or aqueous extract from Radix Glycyrrhizae inflatae, containing licochalcone A. DE102012213938; 2014
36. Beiersdorf Ag. Skin friendly active ingredient combination against acne comprising 1, 2-decanediol, Licochalcone A, and carnitine. WO117126; 2011
37. Shanghai Zhenxin Chemical Co Ltd. Clary sage oil-containing cosmetic astringent. CN103340781; 2013
38. Shanghai Zhenxin Chemical Co Ltd. Sanguisorba officinalis extract-containing toner. CN103340794; 2013
39. Shanghai Zhenxin Chemical Co Ltd. Matricaria essential oil bath salt. CN103340774; 2013
40. Shanghai Bafang Fine Chemical. Bath salt containing rose essential oils. CN103284917; 2013
41. University-Industry Cooperation Group of Kyung Hee. Novel uses of licochalcone A. WO144854; 2012
42. University-Industry Cooperation Group of Kyung Hee. Licochalcone A for the treatment of metabolic disorders. EP2700402; 2011
43. Inst Radiation Med Amms Pla. Application of licochalcone A as antiviral agent. CN103405402; 2013
44. Lotte Co. Ltd. Deodorant composition containing extracts of Angelica keiskei for prevention of mouth odor. JP067585; 2013
45. Nanjing Zelang Agri Dev Co Ltd. Method for preparing xanthoangelol from Angelica keiskei. CN102826986; 2012
46. Suzhou Baozetang Medical Tech. Extraction and purification of chalcones from Angelica keisk. CN102911032; 2013
47. Fancl Corp Keio Gijuku. Melanin formation inhibitors and skin-lightening agents containing isobavachalcone. JP184401; 2011
48. Tianjin University of Traditional Chinese Medicine. Application of isobavachalcone for treating neuritic diseases. CN102772393; 2012
49. Fancl Corp. Cholesterol absorption inhibitor containing Psoralea corylifolia. JP216648; 2013
50. Shenyang Chemical Technology University. Psoralen chalcone soluble liquid, its preparation method and application for controlling plant fungal and viral diseases. CN102893986; 2013
51. Hunan Sanwei Biolog Technology Co Ltd. A method of extracting xanthohumol from hops. CN103524321; 2014
52. Weluga Pharm Anstalt. Pharmaceutical composition with olive extract (hydroxytyrosol) and hop extract (xanthohumol) for intranasal application. WO153647; 2011
53. Ocean University China. Application of xanthohumol in preparation of medicine for inhibiting activity of alphaglucosidase or in health product. CN103735537; 2014
54. Jung HG, Lee GY, Hwang YP, et al. Xanthohumol for treating and preventing osteoporosis. KR0120545; 2012
55. Qimin L. Method for improving water solubility of xanthohumol. CN102309766; 2012
56. Yan J. Application of nardoaristolones A in preparing medicine for treatment of gastric cancer. CN103462955; 2013
57. Liu M. Application of nardoaristolones A to manufacture of the medicine for treating endometrium cancer. CN103405406; 2013
58. Zhang Y. Application of nardoaristolones A in preparation of drugs for treating rheumatoid arthritis. CN103393635; 2013
59. Yan J. Application of nardoaristolone A in preparation of a medicament for promotion of small bowel peristalsis. CN103340848; 2013
60. Fang Z. Application of nardoaristolones A in preparation of antitubercular drugs. CN103315991; 2013
61. E.I. du Pont de Nemours and Co. Method for preparing 3-Trifluoromethyl chalcones. US155617;2014
62. Si Chuan University. (E)-1-[8-(5-methoxyl-2, 2-dimethyl-2Hbenzopyranyl)]-3-(4-methoxyphenyl)-2-propylene-1-ketone and analogs thereof, as well as preparation method and use thereof. WO163835; 2013
63. National University of Singapore. Chalcone structure fluorescence dye for embryonic stem cell probe. WO026886; 2012
64. Anhui University of Technology. A process preparing chalcones using polysulfonate ionic liquids as catalysts. CN103193607; 2013
65. Universidad de Extremadura. Empleo de un catalizador heterog-eneo acido en la sintesis de cetonas alfa, beta-insaturadas a partir de aldehidos y cetonas. ES2395061; 2013
66. Shihezi University. Microwave-Assisted phase transfer catalysis as synthetic method of heterocyclic ring-containing chalcone derivatives. CN103408494; 2013
67. Centre National De La Recherche Scientifique. Use of certain metalaccumulating plants for the performance of organic chemistry reactions. WO150197; 2013
68. Nanjing University of Science and Technology. Method for preparing chalcones by fluorous biphasic catalysis with fluoride-free solvent. CN102850202; 2013
69. Yunnan University. Liquid phase combinatorial method for synthesizing hydroxyflavone compound. CN102584765; 2012
70. Chen D, Li Y. New method for synthesizing alpha, beta-unsaturated carbonyl compound via one-pot condensation. CN102786371; 2011
71. Wenzhou University. Process for preparation of chalcone compounds. CN102775288; 2012
72. Dalian University of Technology. Method for preparing alpha, betaunsaturated carbonyl compound. CN102887807; 2013
73. Dangar VR, Borkhataria KN, Shah VR. Synthesis, characterization and antimicrobial activity of pyrazoline & amino cyanopyridine derivatives of with vanillin. Sci Revs Chem Commun 2014;4(1):31-7
74. Crawley LS, Fanshawe WJ. Neighboring group participation in cyclodehydration. A regiospecific isoxazole synthesis. J Heterocyclic Chem 1977;14:531-4
75. Taylor EC, Morrison RW. An unusual molecular rearrangement of an N-Aminopyrimidine. J Org Chem 1967;32:2379-82
76. The Xinjing Technical Institute of Physics & Chemistry. Method for preparation of chalcone amide derivative and its application for treating vitiligo. CN103342653; 2013
77. Aisa A, Niu C, Li G, Mai D. Chalcone benzothiazole amide derivatives as a tyrosinase agonist useful in treatment of vitiligo and their preparation. CN103360338; 2013
78. Genfit. Improved preparation of chalcone derivatives. WO144579; 2011
79. Xuzhou Ruisai Technology Industry Co., Ltd. Synthesis method for 3-phenyl-1-(4-methyl)phenyl-2-bromo-2-propylene-1-one. CN103664563; 2014
80. University of Southern California. Direct trifluoromethylations using trifluoromethane. WO148772; 2012
81. University of Central Florida Research Foundation. Heterogeneous metal-free catalyst. WO089537; 2014
82. Symrise AG. Enzymatic biosynthesis of dihydrochalcones using chalcone isomerase and enoate reductase. US0045233; 2014
83. Liuzhou Gaotong Food Chemicals Co., Ltd. Synthetic method of neohesperidin dihydrochalcone. CN103334119; 2013
84. Gerke T, Kropf C, Huchel U, et al. Preparation of photolabile pro-fragrance materials. WO189646; 2013
85. Guizhou University. Quinazolinyl-chalcone derivatives with high anti-plant virus activity and preparation method and application thereof in preparation of anti-plant virus pesticides. CN103755646; 2014
86. Jiangsu Tiansheng Pharmaceutical Co Ltd. Resveratrol chalcone derivative and preparation method thereof. CN102093191; 2011
87. Sun Yat-sen University. Preparation of chalcone derivatives with antitumor activity. CN103755732; 2014
88. Zhejiang University. Chalcone compound containing piperazine ring useful in treatment of cancer and its preparation. CN103102331; 2013
89. Nanjing University. Preparation of chalcone oxime derivatives useful as immunosuppressants. CN103102283; 2013
90. Shenyang Pharmaceutical University. 2, 2-Dimethylbenzopyran compounds, the preparation and application. CN102532082; 2012
91. Shenyang Pharmaceutical University. Preparation of (E)-1-(5-substituted-2, 2-dimethyl-2H-1-benzopyran-8-yl)-2-propen-1-one derivatives as antitumor agents. CN103382196; 2013
92. Council for Scientific and Industrial Research. Preparation of coumarin and chalcone derivatives as anticancer agents. WO017454; 2012
93. Ahmed K. Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof. INDE00270; 2011
94. Southern California University. Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer. WO016580; 2013
95. Choong Ang Vaccine Laboratories Co., Ltd. Antiviral agents isolated from Cleistocalyx operculatus extra. WO023660; 2012
96. Xiamen University. Preparation of chalcone derivatives and their application as anti-AIDS drug. CN103755541; 2014
97. Yanbian University. 3-(Carboxylalkyl) rhodanine derivatives as antibacterial agents and their preparation, pharmaceutical compositions and use in the treatment of bacterial infection. CN102391262; 2012
98. Colgate-Palmolive Co. Preparation and use of chalcones as enhancers of antimicrobial agents in treatment of oral microbial infections. WO075136; 2011
99. Borate Hanumant Bapurao. Hybrid molecules containing pharmacophores of fluconazole as antifungal agents and their preparation. INMU01750; 2011
100. Kuwano T, Watanabe M, Murase T. Antiinflammatory agents, inflammatory cytokine expression inhibitors, and prostaglandin production inhibitors containing methoxychalcones. JP101329; 2014
101. Sichuan University. (Benzopyranyl) chalcone compounds as inflammatory factor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of inflammations. CN103382195; 2013
102. Univ Konkuk Ind Coop Corp. Preparation of diphenylpropenone compound for the treatment of inflammatory disorder in the nervous system. WO065922; 2013
103. Univ Ewha Ind Collaboration. Cinnamoylbenzene derivatives for treating and preventing inflammation or neurological disorders. KR0024011; 2013
104. Piramal Life Sciences Ltd. Preparation of heterocyclic benzene compounds as cytokine inhibitors for treating inflammatory disorders. WO121505; 2011
105. Wenzhou Medical College. Application of chalcone compounds in preparation of anti-inflammatory drugs and medicines for treating inflammation-Associated diseases. CN102397269; 2012
106. Yan J. Application of Nardoaristolone A in preparation of drugs for treating diabetes by reducing blood glucose. CN103301105; 2013
107. Chengdu Institute of Biology, CAS. Alpha-Fluoro chalcone compounds useful in treatment of type II diabetes and their preparation. CN103254053; 2013
108. Johns Hopkins University. Chalcone derivatives as Nrf2 activators, their preparation and therapeutic use. WO116362; 2012
109. Chung Choon Hee. Curcumin derivative for treating diabetes complications. KR0134039; 2013
110. Toray Industries. Tissue transglutaminase inhibitors containing chalcone derivatives (1-Thienyl-3-phenyl-2-propen-1-ones) and anti-Alzheimer agents containing them. JP180955; 2013
111. ICM-Institut du Cerveau et de la Moelle-epiniere. Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes comprising an inhibitor of the COMT enzyme. WO139931; 2013